Comparison of results per ASPECTS region*
| Region | Prevalence of ASPECTS changes n (%) | Cohen’s κ | 95% CI | Observed percent (95% CI) agreement between NRAD1 and NRAD2 |
| M1 | 24 (6.4%) | 0.57 | 0.39 to 0.75 | 95% (92 to 97) |
| M2 | 64 (17.1%) | 0.54 | 0.43 to 0.66 | 87% (83 to 90) |
| M3 | 26 (6.9%) | 0.34 | 0.12 to 0.56 | 91% (88 to 94) |
| M4 | 28 (7.5%) | 0.45 | 0.23 to 0.66 | 94% (91 to 96) |
| M5 | 46 (12.3%) | 0.59 | 0.45 to 0.72 | 91% (88 to 93) |
| M6 | 20 (5.3%) | 0.56 | 0.36 to 0.77 | 95% (92 to 97) |
| Lentiform nucleus | 104 (27.7%) | 0.58 | 0.44 to 0.71 | 78% (73 to 82) |
| Internal capsule | 33 (8.8%) | 0.44 | 0.26 to 0.62 | 91% (88 to 93) |
| Insula | 183 (48.8%) | 0.56 | 0.48 to 0.64 | 85% (81 to 88) |
| Caudate | 42 (11.2%) | 0.58 | 045 to 0.71 | 91% (88 to 93) |
| Weighted κ – total ASPECTS | 0.56 | 0.51 to 0.61 | ||
| Non-weighted κ – total ASPECTS | 0.39 | 0.32 to 0.45 | 53% (47 to 58) | |
| ASPECTS 0–5 vs 6–10 | 0.66 | 0.49 to 0.84 | 97% (94 to 98) |
ASPECTS, Alberta Stroke Program Early CT Score; NRAD, neuroradiologist.